S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ADMA · ADMA Biologics Inc
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
ADMA Biologics Inc (ADMA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$11.01
-0.23
(-2.09%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$11.01
$10.93
$11.28
52-WEEK RANGE
$11.01
$7.21
$20.46
What's happening
- ADMA is down 2.09% today, trading at $11.01. — Live quote
- Volume today (148,496) is well below its 3-month average of 2,882,220. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $0.16 actual vs. $0.18 estimated (-9.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ADMA
-38.43%
vs S&P 500
-51.21%
1-YEAR RETURN
ADMA
-23.55%
vs S&P 500
-38.11%
6-MONTH RETURN
ADMA
+4.56%
3-MONTH RETURN
ADMA
+30.73%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.16
Est. $0.18
MISS -9.1%
2026-04-26 (Q1 2026)
$0.19
Est. $0.20
MISS -6.9%
2026-01-26 (Q4 2025)
$0.20
Est. $0.19
BEAT +6.0%
2025-10-26 (Q3 2025)
$0.15
Est. $0.15
MISS -2.0%
Valuation Measures & Ratios
Enterprise Value4$2.58B
Forward P/E511.39
PEG Ratio6—
Price / Sales (TTM1)4.91
Price / Book74.75
EV4 / Revenue5.03
EV4 / EBITDA11.58
Profit Margin32.98%
Operating Margin43.40%
Return on Equity (ROE8)39.59%
Return on Assets (ROA9)26.58%
Avg Volume (3M)2,882,220
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.98B | $2.14B | $3.56B | $4.45B | $4.85B |
| P/E | 12.87 | 15.01 | 26.67 | 34.50 | 43.03 |
| Price/Sales | 4.00 | 4.42 | 7.25 | 9.60 | 11.44 |
| Price/Book | 4.85 | 5.49 | 8.25 | 11.18 | 12.98 |
| EV/Revenue | 4.12 | 4.54 | 7.27 | 9.41 | 11.27 |
| EV/EBITDA | 9.62 | 11.32 | 20.27 | — | — |
| ROE | 37.68% | 36.61% | 30.95% | 32.41% | 30.18% |
| ROA | 22.48% | 21.48% | 23.47% | 23.12% | 22.07% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short20,597,867
Change from Prior Settlement-14.91%
% of Float—
Days to Cover (Short Ratio)5.67
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 2.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 33.0%. Finnhub fundamentals ↗
Potential concerns
- Trailing 52-week price return is -23.6%. Finnhub market metrics ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-05; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ADMA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $124.4M | $114.5M | $134.2M | $122.0M | $114.8M | $119.8M | $107.2M | $81.9M |
| Gross profit | $86.3M | $80.8M | $75.6M | $67.2M | $61.1M | $59.7M | $57.5M | $39.1M |
| Operating income | $52.4M | $58.3M | $51.0M | $42.8M | $34.9M | $39.6M | $39.2M | $21.8M |
| Net income | $37.8M | $45.3M | $36.4M | $34.2M | $26.9M | $35.9M | $32.1M | $17.8M |
| EPS (diluted) | $0.16 | $0.19 | $0.15 | $0.14 | $0.11 | $0.15 | $0.13 | $0.08 |
| EPS (basic) | $0.17 | $0.19 | $0.15 | $0.14 | $0.11 | $0.15 | $0.14 | $0.08 |
| Operating margin | $42 | $51 | $38 | $35 | $30 | $33 | $37 | $27 |
| Net margin | $30 | $40 | $27 | $28 | $23 | $30 | $30 | $22 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $684.2M | $665.2M | $624.2M | $568.7M | $558.4M | $510.6M | $488.7M | $390.6M |
| Total liabilities | $276.0M | $274.9M | $146.9M | $137.5M | $160.1M | $137.2M | $139.7M | $158.7M |
| Stockholders' equity | $408.2M | $390.3M | $477.3M | $431.2M | $398.3M | $373.4M | $349.0M | $231.9M |
| Total current assets | $528.2M | $511.2M | $466.5M | $402.7M | $399.6M | $351.8M | $331.4M | $318.2M |
| Total current liabilities | $75.8M | $73.5M | $69.5M | $56.5M | $74.9M | $53.5M | $55.5M | $44.9M |
| Cash & equivalents | $136.0M | $138.2M | $87.6M | $61.4M | $90.3M | $71.6M | $103.1M | $86.7M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $138.2M | $135.9M | $158.4M | $137.7M | $109.7M | $99.4M | $50.0M | $50.1M |
| Inventory | $239.3M | $222.1M | $206.5M | $196.7M | $191.5M | $172.2M | $170.2M | $171.8M |
| Property, plant & equipment | $66.7M | $65.0M | $65.1M | $69.5M | $57.5M | $57.7M | $54.7M | $53.7M |
| Goodwill | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M |
| Intangible assets | $575.0K | $630.0K | $632.0K | $491.0K | $527.0K | $452.0K | $460.0K | $485.0K |
| Accounts payable | $31.7M | $20.5M | $22.5M | $24.0M | $29.8M | $20.6M | $20.2M | $16.0M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | $143.0K | $143.0K | $143.0K | $143.0K |
| Short-term debt | $3.8M | $3.3M | $2.8M | $2.3M | — | — | $0 | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | $192.8M | $193.6M | $69.3M | $70.1M | — | — | $72.3M | — |
| Other non-current liabilities | — | — | $0 | $90.0K | $2.0K | $2.0K | $360.0K | $375.0K |
| Common stock & paid-in capital | $24.0K | $24.0K | $24.0K | $24.0K | $24.0K | $24.0K | $24.0K | $24.0K |
| Retained earnings | -$78.5M | -$116.3M | -$161.7M | -$211.0M | -$247.5M | -$281.7M | -$308.6M | -$420.5M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $29.5M | $58.2M | $35.6M | $13.3M | $21.1M | -$19.7M | $50.2M | $25.0M |
| Investing cash flow | -$2.3M | $2.4M | -$276.0K | -$14.4M | -$2.5M | -$4.7M | -$2.8M | -$1.1M |
| Financing cash flow | -$29.4M | -$10.1M | -$9.1M | -$27.8M | $48.0K | -$7.1M | -$31.0M | -$25.5M |
| Free cash flow | $27.3M | $55.7M | $34.6M | -$1.1M | $18.7M | -$24.4M | $47.5M | $24.0M |
| Capital expenditures | $2.3M | $2.5M | $1.1M | $14.4M | $2.4M | $4.7M | $2.8M | $1.1M |
| Depreciation & amortization | $1.7M | $1.8M | $6.1M | $2.0M | $2.0M | $1.9M | $5.8M | $1.9M |
| Share-based compensation | $6.1M | $6.3M | $15.4M | $5.0M | $5.0M | $4.6M | $11.5M | $3.2M |
| Deferred income taxes | $3.0K | $3.3M | $1.2M | $4.8M | $1.6M | $3.4M | -$84.3M | $0 |
| Change in accounts receivable | $2.4M | -$22.6M | $20.8M | $27.9M | $10.3M | $49.4M | -$141.0K | $20.0M |
| Change in inventory | $17.2M | $15.6M | $9.8M | $5.2M | $19.3M | $2.0M | -$1.6M | -$8.0M |
| Change in accounts payable | $10.1M | -$1.2M | -$2.2M | -$4.9M | $9.3M | $142.0K | $3.9M | $1.6M |
| Share repurchases | $25.1M | $130.2M | $8.9M | $23.0M | $0 | $0 | $0 | $0 |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | $30.0M | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M | $1.2M |
| Operating income | $191.4M | $139.0M | $21.6M | -$39.4M | -$58.4M |
| Net income | $146.9M | $197.7M | -$28.2M | -$65.9M | -$71.6M |
| EPS (diluted) | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 |
| EPS (basic) | $0.62 | $0.85 | $-0.13 | $-0.33 | $-0.51 |
| Operating margin | $38 | $33 | $8 | -$26 | -$72 |
| Net margin | $29 | $46 | -$11 | -$43 | -$89 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $624.2M | $488.7M | $329.2M | $348.5M | $276.3M |
| Total liabilities | $146.9M | $139.7M | $194.0M | $196.5M | $135.1M |
| Stockholders' equity | $477.3M | $349.0M | $135.2M | $152.0M | $141.2M |
| Total current assets | $466.5M | $331.4M | $257.0M | $270.4M | $208.7M |
| Total current liabilities | $69.5M | $55.5M | $49.8M | $39.3M | $30.4M |
| Cash & equivalents | $87.6M | $103.1M | $51.4M | $86.5M | $51.1M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $158.4M | $50.0M | $27.4M | $15.5M | $28.6M |
| Inventory | $206.5M | $170.2M | $172.9M | $163.3M | $124.7M |
| Property, plant & equipment | $65.1M | $54.7M | $53.8M | $58.3M | $50.9M |
| Goodwill | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M |
| Intangible assets | $632.0K | $460.0K | $499.0K | $1.0M | $1.7M |
| Accounts payable | $22.5M | $20.2M | $15.7M | $13.2M | $12.4M |
| Deferred revenue (current) | — | $143.0K | $182.0K | $143.0K | $142.8K |
| Short-term debt | $2.8M | $0 | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Long-term debt | $69.3M | $72.3M | — | — | — |
| Other non-current liabilities | $0 | $360.0K | $419.0K | $350.0K | $397.4K |
| Common stock & paid-in capital | $24.0K | $24.0K | $23.0K | $22.0K | $19.6K |
| Retained earnings | -$161.7M | -$308.6M | -$506.3M | -$478.0M | -$412.1M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $50.4M | $118.7M | $8.8M | -$59.5M | -$112.4M |
| Investing cash flow | -$21.9M | -$8.6M | -$5.0M | -$13.9M | -$13.5M |
| Financing cash flow | -$44.0M | -$58.3M | -$39.0M | $108.9M | $121.0M |
| Free cash flow | $27.8M | $110.4M | $4.0M | -$73.4M | -$125.9M |
| Capital expenditures | $22.6M | $8.2M | $4.8M | $13.9M | $13.5M |
| Depreciation & amortization | $8.0M | $7.7M | $7.6M | $6.4M | $4.8M |
| Share-based compensation | $20.0M | $13.6M | $6.2M | $5.2M | $3.5M |
| Deferred income taxes | $11.0M | -$84.3M | $0 | $0 | — |
| Change in accounts receivable | $108.4M | $22.6M | $11.9M | -$13.1M | $15.3M |
| Change in inventory | $36.2M | -$2.7M | $9.6M | $38.6M | $43.2M |
| Change in accounts payable | $2.3M | $4.2M | $3.8M | $800.0K | $1.4M |
| Share repurchases | $31.9M | $0 | $0 | — | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ADMA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 01:25 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-28 | 4 | 2026-07-24 | View on SEC.gov → |
| 2026-07-17 | 4 | 2026-07-16 | View on SEC.gov → |
| 2026-06-02 | 8-K | 2026-06-02 | View on SEC.gov → |
| 2026-05-28 | 4 | 2026-05-27 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-12 | View on SEC.gov → |
| 2026-05-12 | 4 | 2026-05-11 | View on SEC.gov → |
| 2026-05-06 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-06 | 8-K | 2026-05-06 | View on SEC.gov → |
| 2026-05-04 | 8-K | 2026-05-04 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-01 | View on SEC.gov → |
Recent news
Headlines about ADMA (ADMA Biologics Inc). Links open the publisher — we don’t host full articles.
-
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
Yahoo · 2026-10-20 -
ADMA Biologics Inc (ADMA) Stock Forecasts
Yahoo! Finance Canada · 2026-10-17 -
ADMA Biologics Inc. Stock Grades | ADMA
Barron's · 2026-10-16 -
ADMA Oct 2026 15.000 call (ADMA261016C00015000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-16 -
ADMA Oct 2026 12.000 put (ADMA261016P00012000) stock historical prices and data
Yahoo Finance UK · 2026-10-16 -
(ADMA) and the Role of Price-Sensitive Allocations
Stock Traders Daily · 2026-10-15 -
ADMA Oct 2026 2.000 call (ADMA261016C00002000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-15 -
How Investors May Respond To ADMA Biologics (ADMA) Peer‑Reviewed Validation Of IVIG Safety And Purity
Yahoo · 2026-10-15
No headlines in this category right now — try “All”.